These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 3054182)
1. Group A streptococcus vaccine may be ready for phase I clinical trials in late 1989. Raymond CA JAMA; 1988 Nov; 260(19):2778. PubMed ID: 3054182 [No Abstract] [Full Text] [Related]
2. [Further study of the prevention of streptococcal infections in experiments on monkeys]. Keller V; Dzhikidze EK; Voskanian NA; Kiunemund O; Knol' G Vestn Akad Med Nauk SSSR; 1986; (3):66-8. PubMed ID: 3518270 [No Abstract] [Full Text] [Related]
3. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines. Bronze MS; McKinsey DS; Beachey EH; Dale JB Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732 [No Abstract] [Full Text] [Related]
4. The future streptococcal M. vaccine against rheumatic fever. Imran M; Jan A J Pak Med Assoc; 1988 Jul; 38(7):176-7. PubMed ID: 3149682 [No Abstract] [Full Text] [Related]
5. [Primary prevention of rheumatism: the status and outlook (vaccine)]. Rotta Y Ter Arkh; 1985; 57(11):97-100. PubMed ID: 3909476 [No Abstract] [Full Text] [Related]
6. Intranasal immunisation of mice with a streptococcal peptide-based vaccine. Relf W; Hayman W; Russell-Jones G; Good M Adv Exp Med Biol; 1997; 418():859-61. PubMed ID: 9331788 [No Abstract] [Full Text] [Related]
7. Changing epidemiology of acute rheumatic fever in the United States. Lee GM; Wessels MR Clin Infect Dis; 2006 Feb; 42(4):448-50. PubMed ID: 16421786 [No Abstract] [Full Text] [Related]
8. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155 [TBL] [Abstract][Full Text] [Related]
9. Group A and group B streptococcal vaccine development. A round table presentation. Dale JB; Cleary PP; Fischetti VA; Kasper DL; Musser JM; Zabriskie JB Adv Exp Med Biol; 1997; 418():863-8. PubMed ID: 9331789 [TBL] [Abstract][Full Text] [Related]
13. Prospects for a group A streptococcal vaccine. McMillan DJ; Chhatwal GS Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524 [TBL] [Abstract][Full Text] [Related]
14. Protection against streptococcal pharyngeal colonization with vaccines composed of M protein conserved regions. Fischetti VA; Bessen DE; Schneewind O; Hruby DE Adv Exp Med Biol; 1991; 303():159-67. PubMed ID: 1805563 [No Abstract] [Full Text] [Related]
15. Changing streptococci and prospects for the global eradication of rheumatic fever. Stollerman GH Perspect Biol Med; 1997; 40(2):165-89. PubMed ID: 9058950 [No Abstract] [Full Text] [Related]
16. Group A streptococcal antigens and vaccine potential. Kehoe MA Vaccine; 1991 Nov; 9(11):797-806. PubMed ID: 1722063 [TBL] [Abstract][Full Text] [Related]
17. Group A streptococcal vaccines. Dale JB Infect Dis Clin North Am; 1999 Mar; 13(1):227-43, viii. PubMed ID: 10198801 [TBL] [Abstract][Full Text] [Related]
18. Status of research and development of vaccines for Streptococcus pyogenes. Steer AC; Carapetis JR; Dale JB; Fraser JD; Good MF; Guilherme L; Moreland NJ; Mulholland EK; Schodel F; Smeesters PR Vaccine; 2016 Jun; 34(26):2953-2958. PubMed ID: 27032515 [TBL] [Abstract][Full Text] [Related]
19. Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Fischetti VA; Hodges WM; Hruby DE Science; 1989 Jun; 244(4911):1487-90. PubMed ID: 2660266 [TBL] [Abstract][Full Text] [Related]
20. M-Protein Analysis of Streptococcus pyogenes Isolates Associated with Acute Rheumatic Fever in New Zealand. Williamson DA; Smeesters PR; Steer AC; Steemson JD; Ng AC; Proft T; Fraser JD; Baker MG; Morgan J; Carter PE; Moreland NJ J Clin Microbiol; 2015 Nov; 53(11):3618-20. PubMed ID: 26292296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]